Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on March 26, 2024. Effective March 26, 2024, the Company's common stock will be eligible for quotation and trading on the "over the counter" market operated by the OTC Markets Group Inc. (the "OTC Market").
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/3/2021 | $3.50 → $2.50 | Buy | HC Wainwright & Co. |
| 9/13/2021 | $7.00 → $3.50 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $6.00 → $5.00 | Outperform | RBC Capital |
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three and twelve months ended December 31, 2023 and provided a corporate update. "2023 was a year for Agile that we believe demon
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference CallDateThursday, March 28, 2024Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics
Appointment of Experienced HR Executive Suzanne Hinchcliffe to Chief People Officer Continues Buildout of Experienced Leadership Team GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer. This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer a
Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer. Appointment of Ernie De Paloantonio to
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. ("Agile") (OTCQB:AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. ("Insud") a global pharmaceutical group based in Spain with a 45-year track record and a presence in over 50 countries. The former holders of Agile common stock voted to approve the acq
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. ("Agile") (OTCQB:AGRX), a women's healthcare company, today announced that it has entered into a definitive merger agreement ("Merger Agreement") with
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.51) by 23.53 percent. The company reported quarterly sales of $5.72 million which beat the analyst consensus estimate of $3.75 million by 52.35 percent. This is a 49.91 percent increase over sales of $3.81 million the same period last year.
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.
Agile Therapeutics (OTC:AGRX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:05 AM. Here's what investors need to know about the announcement. Earnings Agile Therapeutics missed estimated earnings by -59.0%, reporting an EPS of $-1.46 versus an estimate of $-0.92. Revenue was down $381 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.37 which was followed by a 2.0% drop in the share price the next day. Here's a look at Agile Therapeutics's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -1.84 -3.48 -7.50 -11.5 EPS Actual -1.47 -3.10 -7.76 -9 Revenue Estimate 5.27M 4.68M 3.40M 3.
RW - AGILE THERAPEUTICS INC (0001261249) (Filer)
EFFECT - AGILE THERAPEUTICS INC (0001261249) (Filer)
EFFECT - AGILE THERAPEUTICS INC (0001261249) (Filer)
HC Wainwright & Co. reiterated coverage of Agile Therapeutics with a rating of Buy and set a new price target of $2.50 from $3.50 previously
HC Wainwright & Co. reiterated coverage of Agile Therapeutics with a rating of Buy and set a new price target of $3.50 from $7.00 previously
RBC Capital reiterated coverage of Agile Therapeutics with a rating of Outperform and set a new price target of $5.00 from $6.00 previously